MDCO-216 - Novartis
The Medicines Company: J.P. Morgan Healthcare Conference (The Medicines Company) - Jan 9, 2013 - Anticipated launch in US for dyslipidemia in 2017 or beyond; Anticipated launch in Europe and Middle East for dyslipidemia in 2017 or beyond; Anticipated launch in Asia / Pacific region for dyslipidemia in 2017 or beyond 
Anticipated launch Europe • Anticipated launch non-US • Anticipated launch US Dyslipidemia
http://www.larvolonline.com/tlg/ccdb/TheMedicinesCompanyJPMorganHealthcareConferenceJan082013.pdf
 
Jan 9, 2013
 
 
d478ea46-3bbb-4bc0-8ad9-a4656188a0c7.jpg